Drug intelligence / Profile preview

Florastamin

Development stage: Unknown
Lead developer: Healthcare Realty Trust
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Florastamin (18F-AlF-P16-093) is a PSMA-targeting radiopharmaceutical developed by HTA Co., Ltd. (a subsidiary of China Isotope & Radiation Corporation) for the diagnostic imaging of prostate cancer. It consists of a small molecule ligand labeled with the positron-emitting isotope fluorine-18 (18F) that binds specifically to the Prostate-Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase 2. PSMA is highly overexpressed on the surface of prostate cancer cells, including primary tumors and metastatic lesions. By binding to this target, Florastamin enables high-resolution Positron Emission Tomography/Computed Tomography (PET/CT) imaging, allowing for the sensitive detection, staging, and localization of prostate cancer in patients with intermediate-to-high-risk disease or suspected recurrence. It is currently in Phase 3 clinical development in China.

Brand names: Florastamin
Other names: Florastamin[18F] Injection[18F]Florastamin Injectionbetamethasone + dexchlorpheniramine-HTA Co., Ltd.-prostate cancer

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on Florastamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Florastamin.

Explore the full profile